Table 1 Patient Demographics and Treatment Characteristics
Demographic or Clinical Characteristic | No. of patients | % |
|---|---|---|
Median age, years (range) | 66 (44.3–83.3) | |
Median follow-up, months (range) | 47.3 (1–76.9) | |
Gender | ||
Male | 35 | 76.1 |
Female | 11 | 23.9 |
Histology | ||
Squamous | 22 | 47.8 |
Non-squamous | 24 | 52.2 |
Performans Status - ECOGa | ||
0 | 27 | 71.1 |
1 | 11 | 28.9 |
Missing | 8 | |
Location of relapse | ||
Central | 24 | 52.2 |
Peripheral | 22 | 47.8 |
In-field relapse | ||
Yes | 29 | 63 |
No | 17 | 37 |
Primary stage (at first irradiation) | ||
IIIA | 21 | 45.7 |
IIIB | 25 | 54.3 |
Concurrent chemotherapy at first irradiation | ||
Yes | 35 | 76.1 |
No | 11 | 23.9 |
Surgery immediately after the first irradiation | ||
Yes | 11 | 23.9 |
No | 35 | 76.1 |
First irradiation | ||
Median total dose | 66 Gy (44–70) | |
Median dose per fraction | 2 Gy (1.8–2.3) | |
Total dose < 60 Gy | 7 patients | |
Median BED dose | 79.2 Gy (39–90) | |
Concomitant chemotherapy (first irradiation) | ||
Cisplatin - Docetaxel | 17 | 54.8 |
Carboplatin – Paclitaxel | 3 | 9.7 |
Cisplatin – Navelbine | 3 | 9.7 |
Carboplatin – Etoposide | 2 | 6.5 |
Carboplatin - Docetaxel | 2 | 6.5 |
Cisplatin – Paclitaxel | 1 | 3.2 |
Cisplatin – Etoposide | 1 | 3.2 |
Carboplatin – Gemcitabine | 1 | 3.2 |
Carboplatin - Navelbine | 1 | 3.2 |
Unknown | 4 | |
Reirradiation | ||
Median delay between irradiations | 22.6 (6.2–101.5) | |
Median tumor size in mm | 33 (10–60) | |
Median GTV in mL | 13.2 mL (1.1–79.1) | |
Median duration of treatment in days | 5 (3–12) | |
Median total physical prescribed dose in Gy | 60 (40–75) | |
Median prescribed dose per fraction in Gy | 16 (10–20) | |
Median number of sessions | 4 (3–5) | |
Median BEDisocenter in Gy | 132 (72–187.5) | |
Median BED in Gy | 50.2 (6.7–189.1) | |
Isodose of prescription in % | 80 (70–83) | |
Median GTV coverage in % | 95.6 (43.8–100) | |
Median PTV coverage in % | 90.2 (34.8–100) | |
Adjuvant chemotherapy after reirradiation | ||
Yesa | 10 | 21.7 |
No | 36 | 78.3 |